Compare Kinross Gold Corporation (KGC) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs BIO-TECHNE Corp — how do they compare? Kinross Gold Corporation trades at $27.35 (market cap $32.46B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Kinross Gold Corporation is far larger — about 2.9× BIO-TECHNE Corp's market cap, and Kinross Gold Corporation pays the higher dividend (0.58%). Which is the better fit depends on your goals.
| KGC | TECH | |
|---|---|---|
Market Cap | $32.46B | $11.24B |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $72.29 |
52-Week Low | $18.70 | $43.31 |
Enterprise Value | $30.54B | $11.32B |
Dividend Yield | 0.58% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold (KGC) trades at $27.64, up 7.88% with strong momentum following recent earnings beats. The stock shows bullish technical signals with robust fundamentals including 37.52% net margins and 36.95% ROE. Recent S&P credit upgrade to 'BBB' and consistent dividend payments support positive sentiment. Valuation remains attractive with P/E of 10.51 and EV/EBITDA of 5.48.
Outlook remains positive with projected revenue growth to $8.5B in 2026 and strong free cash flow generation. Key risks include gold price volatility and operational execution. Analyst consensus favors Buy with $37.20 price target representing 35% upside potential from current levels.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
